2 new malaria treatments announced as drug resistance grows

Article content

NEW YORK (AP) — Researchers on Wednesday reported two promising new approaches to counteract malaria’s growing resistance to medication — one involving a new class of drugs.

Article content

Switzerland-based Novartis released results of what it called a next-generation treatment. A study of its experimental drug in 12 African countries found it works well against the mosquito-borne parasite that causes malaria and seems to block spread.

Article content

Article content

The drug, called GanLum, is not yet licensed and more than a year away from being available.

Article content

Article content

It’s needed, said Dr. David Sullivan, a malaria expert at Johns Hopkins University.

Article content

Article content

The parasite that causes the disease is developing resistance to existing drugs, meaning “the ice is thinning,” Sullivan said. “It hasn’t given way, but we’re concerned.”

Article content

GanLum has been given as a packet of tiny powder-like granules, once daily for three days. But getting people to take malaria drugs over several days has been challenging — some stop after one or two doses makes them feel better. Experts say a third or more of malaria patients fail to complete the current standard three-day treatment course, a problem that can encourage drug resistance and allow curable cases to intensify.

Article content

In an effort to offer a one-time treatment, another team of researchers said an experiment in West Africa found a single dose of four widely available malaria drugs proved to be an effective cure.

Article content

The two studies were presented Wednesday at the American Society of Tropical Medicine and Hygiene conference in Toronto.

Article content

Parasite has repeatedly developed drug resistance

Article content

Malaria is caused by a parasite that spreads through mosquito bites. Infected people can suffer fever, chills and flu-like illness that, if left untreated, can lead to severe complications and death. It’s mainly found in tropical and subtropical climates. The largest death toll in recent years has been seen in children in sub-Saharan Africa.

Article content

Article content

The medical battle against malaria has ebbed and flowed, as new drugs come along, but the parasite gradually develops the ability to resist them.

Article content

At the beginning of this century, for example, resistance to the drug chloroquine was widespread and malaria killed more than 1.8 million people per year. But then came a class of drugs known as artemisinins, which worked well and helped drive a dramatic decline in global malaria death rates.

Article content

Artemisinin-based compounds remain the first-line treatment in most cases. But signs of partial resistance have been reported, and — for several reasons — malaria death rates have plateaued or even started to rise in some parts of the world.

Article content

Study tested 4-drug combo

Article content

Dr. Ghyslain Mombo-Ngoma led a study in Gabon in which researchers gave a single-dose treatment combining an artemisinin with three other antimalarial medications — pyronaridine, sulfadoxine, and pyrimethamine.

Article content

From May 2024 to October 2025, he and his colleagues treated more than 1,000 patients, half of them younger than 10, who were sick with malaria but not suffering life-threatening symptoms. A little over half got the four-drug, one-time treatment. The rest got a standard, artemisinin-based treatment.